MONTREAL, QUEBEC--(MARKET WIRE)--Aug 10, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News), a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer, announced today the second quarter 2007 financial results and provided an update on its development program.
